CG Oncology, Inc. · NASDAQ:CGON

CG Oncology — Investor Presentation (November 2026)

31 slides from CG Oncology's investor presentation, Nov 16, 2026

  1. Slide 1: Attacking Bladder Cancer for a Better Tomorrow

    Attacking Bladder Cancer for a Better Tomorrow™ Exhibit 99.2

  2. Slide 2: Disclaimer and Forward-Looking Statements

    Disclaimer and Forward-Looking Statements We caution you that this presentation contains forward-looking statements about us and our industry. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and

  3. Slide 3: The Promise of Cretostimogene

    The Promise of Cretostimogene Potential Best-in-Disease Durability and Efficacy Results BOND-003 Cohort C (BCG UR CIS only)1: 76% CR anytime 46.4% (12-mo) 41.8% (24-mo) BOND-003 Cohort P (BCG UR Papillary only)2 95.7% (3-mo) HG-EFS 84.6% (6-mo) 80.4% (9-mo) CORE-008 Cohort A (BCG Naïve HR CIS)2 88%

  4. Slide 4: Comprehensive Programs in High-Risk and Intermediate-Risk NMIBC

    Comprehensive Programs in High-Risk and Intermediate-Risk NMIBC to Address a Multi-Billion Dollar Market Opportunity Cretostimogene Monotherapy Ph 1 Ph 2 Ph 3 Milestones / Status BCG-Unresponsive (BOND-003 Cohort C)1 Intermediate-Risk3 (PIVOT-006) BCG-Naïve High-Risk (CORE-008 Cohort A) BCG-Exposed

  5. Slide 5: Cretostimogene's Dual Mechanism of Action

    Cretostimogene’s Dual Mechanism of Action: Selective Tumor Killing Triggers Durable Anti-Tumor Immune Response Progeny viruses are released and enter new cancer cells Cretostimogene designed to stimulate cytokine and antigen release 1a 1b Attacking Bladder Cancer for a Better Tomorrow™ Cancer Cell C

  6. Slide 6: NMIBC Represents a Multi-Billion Dollar Market Opportunity in Bladder Cancer

    Bladder wall Lamina Propria Inner Muscle Deep Muscle Inside of the bladder wall Outside of the bladder wall Carcinoma in Situ (CIS) Non-Invasive Papillary Carcinoma Tumor Invades Connective Tissue Tumor Invades Deep Muscle Tumor Invades Perivesical Tissue Tumor Invades Adjacent Tissue and Organs Tum

  7. Slide 7: Patient Journey

    Patient Journey 2 Testing Work-up may include cystoscopy, urine cytology, and imaging (CT scan, MRI) 1 Symptoms Patient presents to primary care and/or urologist with symptoms (hematuria, urinary frequency) 3 TURBT1 TURBT, followed by tumor staging and grading Ongoing Treatment Require surveillance

  8. Slide 8: Cretostimogene is Intravesically Administered, Similar to BCG

    GAG Layer Tumor Standard Catheter Cretostimogene Cretostimogene is Intravesically Administered into the Bladder, Similar to Standard-of-Care BCG Therapy Which Urology Practices Perform Regularly BCG = Bacillus Calmette Guerin. DDM = n-Dodecyl β-D-maltoside. GAG = glycosaminoglycan. Procedure Can Be

  9. Slide 9: Cretostimogene Programs Across High-Risk & Intermediate-Risk NMIBC

    NMIBC (75%) Intermediate-Risk (30%) High-Risk (40%) BCG-Exposed BCG-Unresponsive BOND-003 Ph 3 Monotherapy Cohort C / Cohort P Cretostimogene Programs Across High-Risk & Intermediate-Risk NMIBC Potential to Address More Than 70% of NMIBC Market Note: CORE-001, CORE-008 Cohort B, and PIVOT-006 are in

  10. Slide 10: Cretostimogene Monotherapy for BCG-Unresponsive NMIBC (BOND-003 Cohort C)

    Phase 3 Cretostimogene Monotherapy for BCG-Unresponsive NMIBC (NCT04452591) Cohort C DoR CR at 12 months PFS Additional Endpoints BCG-Unresponsive NMIBC Cretostimogene Single-Arm, Open-Label, Intravesical Administration CR at Any Time (CIS) EFS (Ta/T1) Study Design / Regimen Cohort C = BCG-unrespons

  11. Slide 11: BOND-003 Cohort C Overall Complete Response

    BOND-003 Cohort C Overall Complete Response 75.5% (95% CI, 66.3% - 83.2%) CR (n=83) 25 Overall CR Rate (%) (n=110) 50 75 100 0 Efficacy data cutoff as of June 23, 2025. Efficacy analysis are centrally confirmed. All patients have active disease at baseline prior to enrollment. Received adequate BCG

  12. Slide 12: Complete Response Rate at 24 Months

    Cretostimogene Has Delivered Remarkable Complete Response (CR) Rate at 24 Months Cretostimogene demonstrated long-term DoR compared to approved drugs1 in NMIBC with 41.8% of patients in CR at 24 months 90% of patients in CR at 12 months maintained in CR at 24 months No grade 3+ TRAEs – favorable saf

  13. Slide 13: Footnotes and references for comparative data

    1 These data are not based on head-to-head or comparator studies. Differences exist between study designs and subject characteristics, and caution should be exercised when comparing data across studies. From published data. 2 All 9 ongoing CRs remained in response at the 24-month assessment, as well

  14. Slide 14: High-Grade Event-Free Survival (BOND-003 Cohort P)

    Creto High-Grade Event-Free Survival (HG-EFS) vs. DFS/RFS (by K-M)1 BOND-003 Cohort P reported 95.7%, 84.6% and 80.4% HG Event-Free Survival (EFS) at 3, 6 and 9 months, respectively No serious treatment-related adverse events (TRAEs) and no discontinuations related to cretostimogene No dose delays,

  15. Slide 15: Well Positioned in BCG-UR Papillary Only NMIBC

    Cretostimogene is Well Positioned in BCG-UR Papillary Only NMIBC with Potentially Best-in-Disease EFS Endpoint1 Papillary Only (HG Ta/T1) Trial (Status) BOND-003 COHORT P (Ph3 Ongoing)1 SunRISe-12 QUILT 3.0323 NCT027738494,5 KEYNOTE-0576 Drug Cretostimogene TAR-200 N-803 + BCG Nadofaragene Pembroliz

  16. Slide 16: PIVOT-006 Study Design in Intermediate-Risk NMIBC

    Additional Endpoints Study Design / Regimen Population RFS at 12-month and 24-month PFS Safety Intermediate-Risk (IR) NMIBC (Enrollment Completed) Cretostimogene vs Surveillance/TURBT Randomized (1:1), Two Arms, Open-Label (n=367) Primary Endpoint: RFS Rate Arm A: Cretostimogene following TURBT Indu

  17. Slide 17: Intermediate-Risk Landscape: PIVOT-006 Broad Patient Population

    Cretostimogene (PIVOT-006) (investigational) TAR-210 (MoonRIse-1) (investigational) UGN-102 (Approved) IR NMIBC LG Newly Diagnosed IR NMIBC LG Recurrent HG Ta <3cm (solitary) Adjuvant (non-chemoablative) 50K2 Pts (US TAM) Intermediate-Risk Landscape PIVOT-006 Designed to Evaluate Cretostimogene in a

  18. Slide 18: 68% Improvement in RFS in PIVOT-006

    68% Improvement in RFS Hazard Ratio 95% CI 0.23–0.45 | p<0.0001 Cretostimogene Significantly Improved Recurrence-Free Survival (RFS) in Intermediate-Risk and HG Ta NMIBC PIVOT-006 The median follow-up was 17 months at the time of data cutoff Oct. 26,2026. Recurrence was dated to the first evaluable

  19. Slide 19: Cretostimogene in Combination (CORE-008 Cohort CX)

    Ph 2 Cretostimogene in Combination for BCG-Exposed HR & BCG-Unresponsive NMIBC (Cohort CX) CORE-008 Cohort CX CR at any time CR at 12 months DoR PFS CFS Additional Endpoints HR BCG-Exposed & BCG Unresponsive NMIBC Study Design / Regimen Primary Endpoint: HG-EFS Cohort CX (CIS-containing or HG Ta/T1)

  20. Slide 20: CORE-008 Cohort CX High-Grade Event-Free Survival

    CORE-008 Cohort CX High-Grade Event-Free Survival at 3 and 6-Months (ITT Population) Median follow-up: 6.6 months No significant differences in HG-EFS by arm Consistent response among BCG-UR and BCG-exposed subgroups Arm 1 (Concurrent) Arm 2 (Sequential) Censored Overall Estimated HG-EFS at Month 3

  21. Slide 21: CORE-008 Cohort CX Complete Response Rates

    CORE-008 Cohort CX High Complete Response Rates Observed Within CIS-Containing Population IVE gem 85.7% (95% CI, 67.3% – 96.0%) CR at Anytime (n=24) 25 (n=28) 50 75 100 0 92.3% (95% CI, 74.9% - 99.1%) CR at Anytime (n=24) Intention to Treat Population* Efficacy Evaluable Population** (n=26) Complete

  22. Slide 22: Cretostimogene Monotherapy for BCG-Naïve and BCG-Exposed HR NMIBC (Cohort A and B)

    Phase 2 Cretostimogene Monotherapy for BCG-Naïve High-Risk (HR) and BCG-Exposed HR NMIBC (Cohort A and B) CORE-008 Cohort A & B Cohort A DoR (in CIS) EFS, LG-RFS, CFS Cohort B DoR (in CIS) EFS, LG-RFS, CFS Additional Endpoints BCG-Naïve & BCG-Exposed (Actively Enrolling) Cretostimogene Two Cohorts (

  23. Slide 23: High Initial Response Rates from CORE-008 Cohort A

    High Initial Response Rates from CORE-008 Cohort A CORE-008 Cohort A (n=49*) Overall Complete Response 83.7% (95% CI, 70.33% - 92.7%) CR (n=41) 25 Overall CR Rate (%) (n=49)1 50 75 100 0 CR Landmark Analysis CR Rate, % (95% CI) Original Instillation2 (5-step) 79.2% (57.8, 92.9) 19 out of 24 patients

  24. Slide 24: Advancing Cretostimogene to Optimized Instillation

    Advancing Cretostimogene to Optimized Instillation Optimized Instillation Cohort A data supports optimized instillation Potential meaningful benefit to patients and sites (esp. high-volume centers) with estimated ~20-minute time savings Administered via soft catheter by medical assistant, a urologis

  25. Slide 25: Key Clinical Metrics Driving HCP Treatment Decisions

    Key Clinical Metrics Driving HCP Treatment Decisions in BCG-Unresponsive NMIBC* *Market Research across ~100 US HCPs (n=46 urologists, n=54 uro-oncologists), Survey was fielded Nov-Dec 2025 Chart represents percentages ranking as top 3 factors that drive treatment decisions

  26. Slide 26: Building a Capital-Efficient, High-Touch Launch Approach

    CG is Building a Capital-Efficient, High-Touch Approach in Anticipation of a Successful Launch Across a Concentrated Prescriber Network Field Organization Key Account Managers Health System Directors Regional Business Directors National Account Leads Medical Science Liaisons Field Reimbursement Mana

  27. Slide 27: The Path to 150K+ Addressable Patients

    The Path to 150K+ Addressable Patients NMIBC = Non-muscle invasive bladder cancer; HR = high-risk; IR = Intermediate-risk + HG Ta ≤ 3cm TAM derived from NIH SEER, secondary claims data analytics, and management assumptions 150K+ Annualized WAC of approved therapies in HR NMIBC range from $200K to $6

  28. Slide 28: Catalyst Rich Calendar Through Potential First Approval and Launch

    Catalyst Rich Calendar Through Potential First Approval and Launch Followed by Potential Frontline Bladder Indication Expansion Anticipated Milestones* BCG-UR = BCG-unresponsive. *Note: Timing and achievement of milestone events are based on Company estimates and subject to risks and uncertainties.

  29. Slide 29: Contact Us

    www.CGOncology.com CONTACT US GENERAL INQUIRIES Information@cgoncology.com MEDIA MediaRelations@cgoncology.com

  30. Slide 30: Leadership with Deep Industry Experience

    Leadership with Deep Industry Experience with Track Record of Success in Drug Development and Commercialization Arthur Kuan Chairman, President & Chief Executive Officer 13 years of expertise within the NMIBC space 2020 Forbes 30 Under 30 featured honoree in healthcare Jim DeTore Chief Financial Off

  31. Slide 31: Our Vision and Mission

    Our Vision We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. Our Mission We are focused on developing bladder-sparing therapeutics for patients afflicted with bladder cancer. Attacking Bladder Canc

CG Oncology — Investor Presentation (November 2026) on 6ix